Last reviewed · How we verify
Mitchga (NEMOLIZUMAB)
Mitchga (generic name: NEMOLIZUMAB) is a Interleukin-31 Receptor alpha Antagonist [EPC] Monoclonal antibody drug developed by Maruho Co., Ltd.. It is currently FDA-approved for Pruritus associated with atopic dermatitis.
Nemolizumab works by binding to the interleukin-31 receptor subunit alpha, blocking the action of interleukin-31 and reducing inflammation and itching.
Mitchga is an antibody that inhibits the interleukin-31 receptor subunit alpha. It is classified as an inhibitor and has the synonyms CIM-331, CIM331, NEMLUVIO, and NEMOLIZUMAB.
At a glance
| Generic name | NEMOLIZUMAB |
|---|---|
| Sponsor | Maruho Co., Ltd. |
| Drug class | Interleukin-31 Receptor alpha Antagonist [EPC] |
| Target | Interleukin-31 receptor subunit alpha |
| Modality | Monoclonal antibody |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Think of nemolizumab like a key that locks into a receptor on the surface of immune cells. When it binds, it blocks a signal that tells the cells to produce chemicals that cause itching and inflammation. By blocking this signal, nemolizumab helps to reduce the symptoms of atopic dermatitis.
Approved indications
- Pruritus associated with atopic dermatitis
Common side effects
- Hypersensitivity reactions (Type 1, IgE-mediated)
- Angioedema (facial/peri-ocular)
Serious adverse events
- Hypersensitivity reactions (Type 1, IgE-mediated)
- Angioedema (facial/peri-ocular)
Key clinical trials
- Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
- Proof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO) (PHASE2)
- An Open-label, Phase 2 Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Systemic Sclerosis (PHASE2)
- Nemolizumab to Treat Lichen Planopilaris, a Noncontrolled, Prospective, Pilot Study. (PHASE4)
- Utilization of a Microdevice for Psoriasis and Atopic Dermatitis (PHASE4)
- A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis (PHASE2)
- A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mitchga CI brief — competitive landscape report
- Mitchga updates RSS · CI watch RSS
- Maruho Co., Ltd. portfolio CI
Frequently asked questions about Mitchga
What is Mitchga?
How does Mitchga work?
What is Mitchga used for?
Who makes Mitchga?
What is the generic name of Mitchga?
What drug class is Mitchga in?
What development phase is Mitchga in?
What are the side effects of Mitchga?
What does Mitchga target?
Related
- Drug class: All Interleukin-31 Receptor alpha Antagonist [EPC] drugs
- Target: All drugs targeting Interleukin-31 receptor subunit alpha
- Manufacturer: Maruho Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Pruritus associated with atopic dermatitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing